Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
135.42
+0.46 (0.34%)
Dec 20, 2024, 4:00 PM EST - Market closed
Neurocrine Biosciences Employees
Neurocrine Biosciences had 1,400 employees as of December 31, 2023. The number of employees increased by 200 or 16.67% compared to the previous year.
Employees
1,400
Change (1Y)
200
Growth (1Y)
16.67%
Revenue / Employee
$1,602,000
Profits / Employee
$275,643
Market Cap
13.71B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1,400 | 200 | 16.67% |
Dec 31, 2022 | 1,200 | 300 | 33.33% |
Dec 31, 2021 | 900 | 55 | 6.51% |
Dec 31, 2020 | 845 | 145 | 20.71% |
Dec 31, 2019 | 700 | 115 | 19.66% |
Dec 31, 2018 | 585 | 185 | 46.25% |
Dec 31, 2017 | 400 | 204 | 104.08% |
Dec 31, 2016 | 196 | 76 | 63.33% |
Dec 31, 2015 | 120 | 26 | 27.66% |
Dec 31, 2014 | 94 | 13 | 16.05% |
Dec 31, 2013 | 81 | 3 | 3.85% |
Dec 31, 2012 | 78 | 7 | 9.86% |
Dec 31, 2011 | 71 | 5 | 7.58% |
Dec 31, 2010 | 66 | 1 | 1.54% |
Dec 31, 2009 | 65 | -60 | -48.00% |
Dec 31, 2008 | 125 | -10 | -7.41% |
Dec 31, 2007 | 135 | -132 | -49.44% |
Dec 31, 2006 | 267 | -321 | -54.59% |
Dec 31, 2005 | 588 | 203 | 52.73% |
Dec 31, 2004 | 385 | 40 | 11.59% |
Dec 31, 2003 | 345 | 69 | 25.00% |
Dec 31, 2002 | 276 | 54 | 24.32% |
Dec 31, 2001 | 222 | 34 | 18.09% |
Dec 31, 2000 | 188 | 37 | 24.50% |
Dec 31, 1999 | 151 | 2 | 1.34% |
Dec 31, 1998 | 149 | 41 | 37.96% |
Dec 31, 1997 | 108 | 5 | 4.85% |
Dec 31, 1996 | 103 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Fresenius Medical Care AG | 119,845 |
Baxter International | 60,000 |
Viatris | 38,000 |
Dr. Reddy's Laboratories | 27,048 |
Revvity | 11,500 |
Avantor | 7,570 |
Moderna | 5,600 |
Incyte | 2,524 |
NBIX News
- 1 day ago - Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia - PRNewsWire
- 3 days ago - Neurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And Growth - Seeking Alpha
- 8 days ago - Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia - PRNewsWire
- 8 days ago - US FDA approves Neurocrine Biosciences' genetic disorder drug - Reuters
- 25 days ago - Neurocrine Biosciences to Participate at Investor Conferences in December - PRNewsWire
- 6 weeks ago - Why Neurocrine Biosciences Stock Is Very Attractive At Current Levels - Seeking Alpha
- 6 weeks ago - Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules - PRNewsWire
- 6 weeks ago - Neurocrine Biosciences to Participate at Investor Conferences in November - PRNewsWire